Skin and cancer foundation symptoms and conditions

Singulair/Quinolinic acid - skin conditions and myalgia caused by eosinophils

Dear friends for this one I feel like Gomer Pyle "well g-o-o-l-l-l-y." I have been trying to solve the riddle as to whether Singulair might possibly cause skin conditions and myalgia. I found where a researcher actually injected himself with quinolinic acid to see if it caused a reaction from eosoniphils. So hypothetically if there were less than ideal metabolic or genetic conditions that cause the montelukast molecule to break up into a quinolinic acid by-product before it reached the liver then eosinophils will go to where-ever the quinolinic acid is. In the case of this researcher, the quinolinic acid caused skin inflamation conditions because he injected it into his arm.

This study could apply to any quinoline type drug that could break down into quinolinic acid. Now, we don't have proof whether Singulair can break down into quinolinic acid so the doctors won't buy this one as a fact. It is good, however, for a WHAT IF argument for those who would like to do a wait and see if Singulair caused the problem. This researchers eosinophil count took five weeks to drop back down to normal levels.

Clin Exp Med. 2006 Jun ;6 (2):60-4 16820992 (P,S,E,B) Is the L-tryptophan metabolite quinolinic acid responsible for eosinophilic fasciitis?

R Noakes, L Spelman, R Williamson
Qld Skin and Cancer Foundation, Greenslopes Private Hospital, Newdegate St, Greenslopes 4120, Qld, Australia. rnoakes@lagunacom.com.au
The eosinophilia-myalgia syndrome is accompanied by alterations in L-tryptophan metabolism with elevated levels of L-kynurenine and quinolinic acid having been recorded. It has been suggested that this is due to activation of indoleamine 2,3-dioxygenase by interferon-gamma. It is unknown whether these products of tryptophan metabolism play a role in the pathogenesis of this syndrome and the closely related condition of eosinophilic fasciitis. To explore this possibility, the principal author (RN) received a series of subcutaneous injections of quinolinic acid. A total of 1200 mg was administered over a 1-month period. Peripheral blood eosinophil counts were monitored and biopsies taken for H&E and immunohistochemical stains. Over the 1-month period the eosinophil count rose from 0.3x10(9)/l to 0.8x10(9)/l before falling to 0.4x10(9)/l approximately 5 weeks later. H&E sections showed a mixed infiltrate of eosinophils and neutrophils extending through the reticular dermis and septa of the panniculus. No deep fascia was obtained on biopsy. The immunohistochemical stain for transforming growth factor beta 1 showed staining of endothelial cells and dendritic cells. The interleukin-5 stain was negative. Our results suggest that quinolinic acid may play a role in cutaneous eosinophilic disorders.